SAN DIEGO and CAMBRIDGE, Mass., Dec. 5, 2017 /PRNewswire/ -- Edico Genome and Seven Bridges today announced the availability of Edico Genome's DRAGEN™ pipelines within Seven Bridges' cloud-based data ecosystem. Edico Genome's DRAGEN Germline V2, DRAGEN Somatic V2 and DRAGEN RNA Gene Fusion Detection Pipelines are now live on the Seven Bridges platform, enabling customers to leverage DRAGEN's ultra-rapid speeds and accuracy.
Seven Bridges is a leading biomedical data company and specializes in software and data analytics that help researchers turn raw genomic and clinical data into actionable results. Its data ecosystem is used by thousands of researchers in biotech, pharmaceutical and academic labs, as well as some of the world's largest national genomics research programs, including those led by the National Institutes of Health, Genomics England and the U.S. Department of Veterans Affairs.
"Our customers rely on us to provide a full suite of bioinformatics tools and computational resources to further their research," said Michael Hultner, Ph.D., chief strategy officer at Seven Bridges. "Edico Genome's DRAGEN offers a strong solution for the rapid analysis of sequencing data, with more than 17 petabytes of genomics data processed to date. We are pleased to offer DRAGEN within our secure environment to arm customers with the tools they need to accelerate genomic discoveries."
DRAGEN leverages field-programmable gate array (FPGA) technology to deliver industry leading speeds and scalability. In contrast to 20 to 30 hours using traditional technologies, such as BWA-GATK, DRAGEN is able to analyze a whole human genome at 30x coverage in approximately 25 minutes. The DRAGEN suite of applications on Seven Bridges is enabled through Amazon Web Services' (AWS) EC2 F1 instances, allowing DRAGEN in the cloud to achieve the same industry leading speeds as its onsite solution without the upfront investment costs.
"Seven Bridges is a true leader when it comes to managing, analyzing and connecting the massive amounts of data generated by next-generation sequencing, and works toward the same goal as Edico Genome: removing the hurdles that limit the use of genomic data for biomedical discoveries," said Pieter van Rooyen, Ph.D., president and CEO at Edico Genome. "With the integration of Seven Bridges' and Edico Genome's solutions, scientists and clinicians can now seamlessly access the ultra-rapid and accurate DRAGEN through Seven Bridges' platform, reducing the time spent waiting on data to maximize the time spent on research."
New and existing Seven Bridges customers can analyze ten genomes for free using DRAGEN during the trial period, which runs Dec. 5 through Jan. 31. For more information about the trial and DRAGEN on Seven Bridges, visit: http://edicogenome.com/seven-bridges/
About Edico Genome
The use of next-generation sequencing is growing at an unprecedented pace, creating a need for easy to implement infrastructure that enables rapid, accurate and cost-effective processing and storage of this big data. Edico Genome has created a patented, end-to-end platform solution for analysis of next-generation sequencing data, DRAGEN™, which speeds whole genome data analysis from hours to minutes while maintaining high accuracy and reducing costs. Top clinicians and researchers are utilizing the platform to achieve faster diagnoses for critically ill newborns, cancer patients and expecting parents waiting on prenatal tests, and faster results for scientists and drug developers. For more information, visit www.EdicoGenome.com or follow @EdicoGenome.
About Seven Bridges
Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development, and precision medicine. Thousands of researchers in government, biotech, pharmaceutical, and academic labs use Seven Bridges, including global pharmaceutical companies and national genomics projects such as the U.S. National Cancer Institute's Cancer Genomics Cloud pilot, the Gabriella Miller Kids' First Data Center, the Million Veteran Program, and Genomics England's 100,000 Genomes Project.
SOURCE Edico Genome